
Janssen’s Stelara shows promise across two dosages in ulcerative colitis
pharmafile | October 9, 2018 | News story | Manufacturing and Production, Research and Development | Janssen, Stelara, pharma, ulcerative colitis
Janssen’s biologic therapy Stelara (ustekinumab) has shown new efficacy in the treatment of moderate to severe ulcerative colitis in two dosage groups, with both reporting “statistically significant improvements” as measured on the Inflammatory Bowel Disease Questionnaire (IBDQ).
The drug has already secured approval in the US for a range of conditions including active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderate to severe plaque psoriasis.
In eight-week induction data derived at Phase 2, 15.6% and 15.5% of patients taking 130mg doses or 6mg/kg doses respectively achieved clinical remission, as opposed to just 5.3% of those taking placebo.
Clinical response stood at 51.3% and 61.8% for the same dosage groups, compared to 31.3% for placebo, while 26.3% and 27% experienced endoscopic healing, versus 13.8% for placebo.
“Stelara is the first biologic approved for any indication that targets interleukin (IL)-12 and IL-23 cytokines, which are believed to play a role in immune-mediated diseases, like ulcerative colitis,” said Philippe Szapary, Vice President, Clinical Development at Janssen Research & Development. “These induction data from the Phase 3 UNIFI study underscore the potential for this pathway in the treatment of UC, which may lead to a new effective and safe treatment option for UC patients in the future.”
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …






